Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... Chief Executive Officer, has been elected to the Company,s ... Steven G. Anderson , Executive Chairman of CryoLife, stated, ... to be an excellent leader who is well positioned ...
(Date:10/22/2014)... JERUSALEM , October 22, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused ... today reported positive top-line clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... United States under a U.S. Food ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... CVM ) reports financial results for the fiscal ... operating loss for fiscal year 2007 of $9,352,209,versus a ... The loss per,share for fiscal year 2007 was unchanged ... from operating activities used during the year was about,$4,890,100. ...
... Fla., Jan. 11 Florida Atlantic,University and Scripps ... on Wednesday, January 16 from 4-5:30 p.m. in ... Blobel, M.D., Ph.D.,is the 1999 recipient of the ... D. Rockefeller, Jr. Professor, The Rockefeller University, and,Investigator, ...
Cached Medicine Technology:CEL-SCI Corporation Announces 2007 Financial Results 2CEL-SCI Corporation Announces 2007 Financial Results 3Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University 2Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University 3
(Date:10/25/2014)... home safe and sound is one of the best Halloween ... costumes and goody bags have reflective strips that improve visibility ... at Meadowlands Hospital Medical Center in Secaucus, N.J. ... flame-resistant, Davis said. He offers these others tips: ... a small area of skin first to ensure it doesn,t ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... of transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) ... multidistrict litigation underway in U.S. District Court, Southern ... Motion for Summary Judgment on Punitive Damages in ... Florida plaintiffs. In a ruling issued on October ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... -- herpes simplex -- might increase the risk of Alzheimer,s ... being a carrier of certain antibodies to the virus can ... "The identification of a treatable cause [herpes simplex] of ... researcher Dr. Hugo Lovheim, an associate professor in the department ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Diabetic retinopathy is the most common disorder seen in diabetics. ... a person with diabetes develops diabetic retinopathy,// a major cause ... diabetes is responsible for 7 percent of legal blindness, making ... adults 22 to 70 years old. ,Researchers from the ...
... can block the death of brain cells in mice who ... (HD), which is a rare degenerative brain disorder //caused by ... may be one step closer to a treatment, according to ... treated with a bile acid known as tauroursodeoxycholic acid (TUDCA), ...
... shows people with diabetes who are in a happy ... unhappily married counterparts. Researchers from the State University of ... adults with diabetes who had been married for an ... insulin, were surveyed again two years after the initial ...
... the University in Boston, a person's degree of inhibition when ... tied to his or her likelihood of being overweight. The ... low-calorie foods--can help people who just can't seem to resist ... B. Roberts. The reasons why some people are able to ...
... According to a new study, it has been found ... as you age. Mental decline is not a specific part ... are typically living longer. The ability to know, think, learn ... of life and survival in older ages. Researchers from the ...
... cancer all over the world. More than 30,000 women ... breast cancer this year. Researchers now believe small family ... fueling this ever-growing epidemic.// ,Researchers from England ... information on breastfeeding and childbearing patterns. Together, the studies ...
Cached Medicine News:Health News:Stop and think before you eat 2Health News: Breastfeeding may decrease Breast Cancer Risk 2
The ultimate replacement device, the Contour MD ICD offers a maximum stored energy of 42 J. The device delivers high-energy defibrillation output and is ideal for patients with maximum energy defibri...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... catheters comprise the world's broadest line ... procedures. Their advanced catheter design and ... response with a soft, atraumatic tip. ... sizes, Supreme and Response catheters provide ...
Medicine Products: